Contact us Career


global wound biologics market report 2018 2024

Global Wound Biologics Market Report 2018-2024

pages Pages: 72
tables Tables: 20
charts Charts: 32
country Regions/Countries: 4/8
compaines Companies: 10
enqhours Enquiry Hours: 10
  • Get Free 10% Customization in this Report

COVID - 19

Covid impact updated reports at special price

Overview: Wound care products are mainly intended for safeguarding timely wound healing and active control of infection. There are many wound products accessible in the market, from over-the-counter to prescription products. Maximum wound care products are topical and are permitted as medical devices, but a few products such as biologics are scrutinized under strict regulatory guidelines. The wound biologics market is very unified at present, with the US, Europe, and Japan collectively accounting for a significant share of the product sales. The principal variables are the regulatory trails essential for obtaining marketing approval, with the US regulatory necessities being very different when compared to most of the other nations. Furthermore, the standard of care fluctuates significantly between industrialized and emerging countries, making it tougher to conduct sufficiently precise clinical trials in a global setting.

Skin substitutes, growth factors, and enzyme-based products are the major types of biologics in the market. Nearly half of the skin substitute market is dominated by the major players in the market. Organogenesis, Molnlycke, and Smith & Nephew are the major players in this segment.

The growth of the market is driven by an increase in aging population, increasing number of people suffering from diabetes, growing acceptance of innovative technologies for complex wound treatment, and rising incidence of chronic wounds. However, the complex regulatory process and the high cost of biologic wound care are hampering the market growth.

Market Analysis: The “Global Wound Biologics Market” is estimated to witness a CAGR of 12.3% during the forecast period 2017–2023. The market is analyzed based on four segments – products, applications, end-users, and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the global wound biologics market, followed by Europe, Asia Pacific, and Rest of the World. Nearly half of the market is occupied by North America, with the US being the major contributor to the market growth. In the US, Organogenesis and MiMedx hold nearly half of the skin substitutes market. However, Europe is close to North America with many companies developing advanced technology products. In Germany, Organogenesis and Integra Life Science hold a significant share of the skin substitutes market.

Product Analysis: Skin substitutes, growth factors, and enzyme-based products are the types of wound closure biologics in the market. Skin substitutes is the major segment of the market. MiMedx, Organogenesis, and Smith and Nephew are the key players in the skin substitute market. MiMedx increased its market share from 24.9% in 2015 to 31% in 2016 in the advanced skin substitute market.

Application Analysis: The applications of the wound biologics include chronic wound and acute wound. Acute wound comprises traumatic wound and surgical wound. As the ratio of the surgical wound is higher in comparison with other wound types, the acute wound closure was the major shareholder of the market in 2017. However, the chronic wound is increasing the burden of healthcare expenditure globally. This has increased the demand for innovative products for the treatment, which is expected to experience the fastest growth rate during the forecast period.

Key Players: Organogenesis, Smith & Nephew, MiMedx, and Integra Life Science are the key players in the market. The other prominent players in the market include Pinnacle Transplant, Osiris, Molyncke Health Care, Soluble Systems, Applied Biologics, and Skye Medical.

Competitive Analysis: Many players are using various strategies such as new product launches, clinical trials, market initiatives, high expense on R&D, agreements, joint ventures, acquisitions, and others to increase their footprints in this market. In January 2018, Alliqua BioMedical, Inc. entered a definitive agreement with Celularity, Inc. to acquire all the assets and rights of the company’s advanced biologic wound care business. This added Biovance Amniotic Membrane Allograft, Interfyl Human Connective Tissue Matrix, UltraMist Therapy System, and other therapeutic products to Alliqua’s portfolio. In January 2016, Human Regenerative Technologies, LLC initiated the building process of its new state-of-the-art amniotic and placental tissue matrix research, development, and processing facility worth $12 million in California, US.

Benefits: The report provides complete details about the usage and adoption rate of wound biologics in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

wound biologics stakeholders
1              Industry Outlook

 1.1          Industry Overview

1.2          Industry Trends

2              Report Outline

2.1          Report Scope

2.2          Report Summary

2.3          Research Methodology

2.4          Report Assumptions

3              Market Snapshot

3.1          Total Addressable Market

3.2          Market Definition – Infoholic Research

3.3          Segmented Addressable Market

3.4          Trends in Wound Care Biologics Market

3.5          Related Markets

3.5.1      Active Pharmaceutical Ingredients

3.5.2      Diabetes Drugs

3.5.3      Regenerative Medicine

3.5.4      Oncology (Cancer) Drugs

4              Market Outlook

4.1          Regulatory Outlook

4.2          Market Segmentation

4.3          Porter 5(Five) Forces

4.4          PEST Analysis

5              Market Characteristics

5.1          Market Dynamics

5.1.1      Drivers   Increasing aging population   Rising incidence of chronic wounds   Increasing number of people suffering from diabetes   Increasing acceptance of innovative technologies for complex wound treatment

5.1.2      Opportunities   Increase in healthcare spending   Untapped emerging market in developing countries

5.1.3      Restraints   Complex regulatory process   High cost of biologic wound care

5.2          DRO – Impact Analysis

5.3          Key Stakeholders

6              Types: Market Size and Analysis

6.1          Overview

6.2          Growth Factors

6.3          Skin Substitutes

6.4          Enzyme-based Products

7              Application: Market Size and Analysis

7.1          Overview

7.2          Chronic Wound

7.3          Acute Wound

8              End-users: Market Size and Analysis

8.1          Overview

8.2          Hospitals & Clinics

8.3          Ambulatory Surgical Centers

9              Regions: Market Size and Analysis

9.1          Overview

9.2          North America

9.2.1      Overview

9.2.2      US

9.2.3      Canada

9.3          Europe

9.3.1      Overview

9.3.2      UK

9.3.3      Germany

9.4          Asia Pacific

9.4.1      Overview

9.4.2      India

9.4.3      China

9.5          Rest of the World

9.5.1      Overview

9.5.2      Middle East & Africa

9.5.3      Brazil

10           Competitive Landscape

11           Vendor Profiles

11.1        Smith & Nephew, Inc.

11.1.1    Overview

11.1.2    Geographic Revenue

11.1.3    Business Focus

11.1.4    SWOT Analysis

11.1.5    Business Strategies

11.2        Organogenesis Inc.

11.2.1    Overview

11.2.2    Business Focus

11.2.3    SWOT Analysis

11.2.4    Business Strategies

11.3        MiMedx

11.3.1    Overview

11.3.2    Business Focus

11.3.3    SWOT Analysis

11.3.4    Business Strategies

11.4        Integra Life Sciences Corp.

11.4.1    Overview

11.4.2    Geographic Revenue

11.4.3    Business Focus

11.4.4    SWOT Analysis

11.4.5    Business Strategies

12           Companies to Watch For

12.1        Pinnacle Transplant Technologies

12.1.1    Overview

12.2        Osiris Therapeutics, Inc.

12.2.1    Overview

12.2.2    Highlights

12.3        Mölnlycke Health Care AB

12.3.1    Overview

12.4        Soluble Systems, LLC

12.4.1    Overview

12.4.2    Highlights

12.5        Applied Biologics

12.5.1    Overview

12.6        Skye Biologics

12.6.1    Overview



Research Framework

Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:

  • Data Collation (Primary & Secondary)
  • In-house Estimation (Based on proprietary data bases and Models)
  • Market Triangulation
  • Forecasting

Market related information is congregated from both primary and secondary sources.

Primary sources

Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.

Secondary sources

Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.


Global Wound Biologics Market Report 2018-2024
Interested in this report?
Get your FREE sample now!

Select User License


Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer 10% worth of FREE customization at the time of purchase

Speak to our analyst
Related Reports